The tumor evolution leading to castration-resistant prostate cancer is accompanied by acquiring DNA mutations including mutations in the ligand binding domain (LBD) of the AR, amplification of AR, or non-classic activation of AR signaling that overcome inhibition by AR antagonists (Le et al. 2023; Ehsani et al. 2021). This evidence concerns the gene AR and neoplasm.